Cravens & Co Advisors’s AdvisorShares Pure US Cannabis ETF MSOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$63.3K Hold
17,818
0.04% 63
2025
Q4
$85.7K Buy
17,818
+850
+5% +$3.79K 0.06% 62
2025
Q3
$81.3K Hold
16,968
0.06% 57
2025
Q2
$40.9K Buy
16,968
+1,780
+12% +$4.38K 0.03% 55
2025
Q1
$39.6K Sell
15,188
-13,258
-47% -$42.8K 0.03% 57
2024
Q4
$108K Sell
28,446
-20,062
-41% -$108K 0.08% 60
2024
Q3
$348K Sell
48,508
-945
-2% -$6.71K 0.27% 48
2024
Q2
$362K Hold
49,453
0.27% 53
2024
Q1
$495K Sell
49,453
-1,178
-2% -$10.3K 0.41% 45
2023
Q4
$355K Sell
50,631
-435
-0.9% -$2.89K 0.31% 53
2023
Q3
$405K Buy
51,066
+178
+0.3% +$1.12K 0.38% 48
2023
Q2
$282K Buy
50,888
+19,930
+64% +$109K 0.26% 64
2023
Q1
$176K Buy
30,958
+1,599
+5% +$10.6K 0.16% 71
2022
Q4
$205K Buy
+29,359
New +$302K 0.19% 75

Other funds holding MSOS

Cravens & Co Advisors's MSOS Position: Q1 2026 in Review

Cravens & Co Advisors held its AdvisorShares Pure US Cannabis ETF (MSOS) position steady in Q1 2026 at 17,818 shares worth $63.3K. The position accounts for 0.04% of the portfolio, ranked #63.

Cravens & Co Advisors first reported a position in MSOS in Q4 2022 and has held it in 14 quarters since. The position peaked at $495K in Q1 2024. 168 funds tracked by Wall St. Rank hold MSOS as of Q1 2026.

  • Cravens & Co Advisors held 17,818 shares of AdvisorShares Pure US Cannabis ETF worth $63.3K as of Q1 2026.
  • Cravens & Co Advisors left its AdvisorShares Pure US Cannabis ETF share count unchanged in Q1 2026.
  • AdvisorShares Pure US Cannabis ETF made up 0.04% of Cravens & Co Advisors's portfolio in Q1 2026, its #63 holding.
  • Cravens & Co Advisors first reported a position in AdvisorShares Pure US Cannabis ETF in Q4 2022 and has held it in 14 quarters since.
  • Cravens & Co Advisors's AdvisorShares Pure US Cannabis ETF position peaked at $495K in Q1 2024.
  • 168 funds tracked by Wall St. Rank held AdvisorShares Pure US Cannabis ETF as of Q1 2026.

Based on Cravens & Co Advisors's 13F filing for Q1 2026, filed 14 May 2026.